Effect of T-0632, a CholecystokininA Receptor Antagonist, on Experimental Acute Pancreatitis.
-
- Taniguchi Hiroyuki
- Lead Optimization Research Laboratory, Tanabe Seiyaku Co., Ltd.
-
- Yomota Eiji
- Lead Optimization Research Laboratory, Tanabe Seiyaku Co., Ltd.
-
- Kume Eisuke
- Lead Optimization Research Laboratory, Tanabe Seiyaku Co., Ltd.
-
- Shikano Toshirou
- Lead Optimization Research Laboratory, Tanabe Seiyaku Co., Ltd.
-
- Endo Toshio
- Lead Optimization Research Laboratory, Tanabe Seiyaku Co., Ltd.
-
- Nagasaki Masaaki
- Lead Optimization Research Laboratory, Tanabe Seiyaku Co., Ltd.
書誌事項
- タイトル別名
-
- Effect of T-0632 a CholecystokininA Rec
この論文をさがす
抄録
Effects of a new cholecystokinin (CCK)A-receptor antagonist, T-0632 [sodium (S)-I-(2-flu orophenyl)-2, 3-dihydro-3-[(3-isoquinolinylcarbonyl)amino]-6-methoxy-2-oxo-1H-indole-3-propanoate], on caerulein-induced and pancreatic duct ligation-induced pancreatitis models were studied and compared with the CCKA-receptor antagonist loxiglumide and the orally active protease inhibitor camostate, respectively. In rats, orally administered T-0632 potently prevented the caerulein-induced increases in pancreatic digestive enzymes in plasma and suppressed the histological changes in the pancreas. The estimated ED50 values of T-0632 and loxiglumide were 0.0092 and 8.9 mg/kg, respectively. In dogs, T-0632 (0.1, 1 mg/kg, i.d.)prevented the caerulein-induced increase in plasma amylase activity in a dose-dependent manner. Loxiglumide (100 mg/kg, i.d.)did not show any preventive effects. In pancreatic duct ligation (6 hr)induced pancreatitis of the rat, T-0632 (0.001-0.1 mg/kg, p.o.)partially prevented both the increase in plasma amylase activity and the histological changes in the pancreas, whereas camostate (10, 100 mg/kg, p.o.)did not show any preventive effects. In pancreatic duct ligation (3 hr)-induced pancreatitis, caerulein injection (1 μg/kg, s.c.)caused a further increase in plasma amylase activity, and T-0632 (0.01, 0.1 mg/kg, p.o.)dose-dependently decreased the aggravation by caerulein. We conclude that T-0632 showed preventive effects on all of these pancreatitis models by oral or intraduodenal administration. These results suggest that CCK plays an important role in progression and aggravation of acute pancreatitis, and T-0632 may have a therapeutic value in these disease states.
収録刊行物
-
- Jpn.J.Pharmacol.
-
Jpn.J.Pharmacol. 73 (2), 105-112, 1997
公益社団法人 日本薬理学会
- Tweet
キーワード
詳細情報 詳細情報について
-
- CRID
- 1390282679263675392
-
- NII論文ID
- 10008677028
-
- NII書誌ID
- AA00691188
-
- COI
- 1:CAS:528:DyaK2sXhsVWgtr0%3D
-
- ISSN
- 13473506
- 00215198
-
- NDL書誌ID
- 4153685
-
- PubMed
- 9074944
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- NDL
- Crossref
- PubMed
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可